Inflammatix
  • TriVerity
  • Education
    • Acute Infection & Sepsis
    • Immune Response
    • Machine Learning
    • Advocacy
  • Evidence
    • Publications
    • Abstracts
  • Pipeline
  • News
    • News
    • Press Releases
    • ML Blogs
    • Podcasts
    • Media Contact
  • Careers
  • About
    • Leadership
    • Investors
    • Partner With Us
    • Awards
    • Certificates
  • Reach Out
Select Page
Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up

Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up

Jan 2, 2024

Inflammatix sepsis test scores FDA breakthrough device designation

Inflammatix sepsis test scores FDA breakthrough device designation

Nov 28, 2023

Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up

Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test

Nov 28, 2023

Your medical devices are getting smarter. Can the FDA keep them safe?

Your medical devices are getting smarter. Can the FDA keep them safe?

Oct 9, 2023

Point-of-care testing for infectious diseases in emergency settings

Point-of-care testing for infectious diseases in emergency settings

Jan 18, 2023

« Older Entries
    • TriVerity
    • Education
      • Acute Infection & Sepsis
      • Immune Response
      • Machine Learning
      • Advocacy
    • Evidence
      • Publications
      • Abstracts
    • Pipeline
    • News
      • News
      • Press Releases
      • ML Blogs
      • Podcasts
      • Media Contact
    • Careers
    • About
      • Leadership
      • Investors
      • Partner With Us
      • Awards
      • Certificates
    • Reach Out

    © Copyright 2025, Inflammatix, Inc. All Rights Reserved | Terms & Conditions | Privacy & Cookies Statement
    Inflammatix, TriVerity, Myrna, RespVerity, and BacVerity are trademarks of Inflammatix, Inc.

    • Follow
    • Follow